Onkológia 6/2013

Hormon replacement therapy in patients after the treatment of gynaecological malignancies

Women treated for gynaecological malignancies suffer not only from the oncological disease itself but also from the loss of the ovarian function and climacteric symptoms. Iatrogenic menopause is usually more intense due to its sudden onset, younger age of these patients and the oncological therapy itself. These patients have increased risk of cardiovascular diseases, osteoporosis, arthritis, skin changes, eye changes, mucosal changes of the oral, vulvar, and vaginal region. The most effective treatment of menopausal symptoms is hormone replacement therapy. However, the use of hormone replacement therapy in patients after the treatment of gynaecological malignancies is controversial. Most of these diseases are not estrogen dependent and therefore the use of hormone replacement therapy is safe. However, it is necessary to evaluate the benefits and risks of hormonal replacement therapy in each patient.

Keywords: hormone replacement therapy, gynaecological malignancies, carcinoma.